Black Diamond Therapeutics, Inc.

I am downgrading Black Diamond Therapeutics from Strong Buy to 'Buy' due to slower-than-expected phase 3 initiation for silevertinib in 1st-line non-classical EGFRm NSCLC. BDTX's silevertinib demonstrated a 60% ORR and 86% CNS ORR in phase 2, outperforming current SOC therapies for CNS involvement in this patient subset. Key catalysts in Q4 2026 include updated phase 2 data and crucial FDA feedback on advancing silevertinib to a pivotal phase 3 trial.

Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Insider and Institutional Ownership 95.5% of Black

Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) and Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations. Profitability This table compares Pliant Therapeutics

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D.